ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Venous Thromboembolism

Study type: Observational

Funder types: Industry

Identifiers

NCT02836457

CV185-396

Details and patient eligibility

About

The primary objectives of this study is to estimate the real-world safety profile of Eliquis in Japanese Venous Thromboembolism patients and to estimate the risk factors likely to affect the incidence of bleeding. Lastly, the secondary objective of this study is to estimate the real-world effectiveness profile of Eliquis in Japanese Venous Thromboembolism patients.

Enrollment: 1,134 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are initiating Eliquis for the treatment of VTE or prevention of recurrent VTE for the first time

Exclusion criteria

• Prior treatment with Eliquis for nonvalvular atrial fibrillation or VTE
• Patients initiating Eliquis for the treatment of atrial fibrillation
• Off-label use of Eliquis

Other protocol defined inclusion/exclusion criteria could apply

Trial design

1,134 participants in 1 patient group

Population with Exposure to ELIQUIS (APIXABAN)